{"DataElement":{"publicId":"8024745","version":"1","preferredName":"ALK Tyrosine Kinase Receptor Variation Positive Finding Neoplasm Amino Acid Sequence Change Other Specify","preferredDefinition":"The free-text field to describe other amino acid sequencing changes detected in the ALK tyrosine kinase receptor variation positive finding neoplasm.","longName":"ALK_TKR_VR_NEO_AA_CHNG_SP","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"5790457","version":"1","preferredName":"ALK Tyrosine Kinase Receptor Variation Positive Finding  Neoplasm Amino Acid Sequence Change","preferredDefinition":"ALK tyrosine kinase receptor (1620 aa, ~176 kDa) is encoded by the human ALK gene. This protein is involved in ligand binding, tyrosine phosphorylation and signal transduction._A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism._An alteration or difference from a norm or standard._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._The arrangement of amino acids in a protein. Proteins can be made from 20 different kinds of amino acids, and the structure and function of each type of protein are determined by the kinds of amino acids used to make it and how they are arranged._The act of alteration or modification; changed or altered in form or character.","longName":"5790454v1.0:5790455v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"5790454","version":"1","preferredName":"ALK Tyrosine Kinase Receptor Positive Finding Variation Neoplasm","preferredDefinition":"ALK tyrosine kinase receptor (1620 aa, ~176 kDa) is encoded by the human ALK gene. This protein is involved in ligand binding, tyrosine phosphorylation and signal transduction.:A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.:An alteration or difference from a norm or standard.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","longName":"C27032:C38758:C25713:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ALK Tyrosine Kinase Receptor","conceptCode":"C27032","definition":"ALK tyrosine kinase receptor (1620 aa, ~176 kDa) is encoded by the human ALK gene. This protein is involved in ligand binding, tyrosine phosphorylation and signal transduction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Positive Finding","conceptCode":"C38758","definition":"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Variation","conceptCode":"C25713","definition":"An alteration or difference from a norm or standard.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E280779-FEC3-1098-E053-F662850A5F55","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5790455","version":"1","preferredName":"Amino Acid Sequence Change","preferredDefinition":"The arrangement of amino acids in a protein. Proteins can be made from 20 different kinds of amino acids, and the structure and function of each type of protein are determined by the kinds of amino acids used to make it and how they are arranged.:The act of alteration or modification; changed or altered in form or character.","longName":"C13187:C25446","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amino Acid Sequence","conceptCode":"C13187","definition":"The sequence of amino acids along a polypeptide chain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Change","conceptCode":"C25446","definition":"The act of alteration or modification; changed or altered in form or character.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E280779-FED1-1098-E053-F662850A5F55","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008547","version":"1","preferredName":"Specimen Characteristics","preferredDefinition":"attributes of a patient's laboratory sample, including the source, condition, and fixative.","longName":"SPEC_CHAR","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22908C4-638F-4A74-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E280779-FEE2-1098-E053-F662850A5F55","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"KUMMEROA","dateModified":"2022-02-02","changeDescription":"2022-2-2 ak Released. Workflow and Registration Status Changed per Brenda Duggan; 05.16.18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2666713","version":"2","preferredName":"Other Specify","preferredDefinition":"Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.","longName":"OTH_SPEC","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208051","version":"1","preferredName":"Other Specify","preferredDefinition":"Not otherwise specified.:Specify; be specific about something; define clearly.","longName":"C17649:C25685","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3B5E-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"132D4785-528E-5337-E050-BB89AD433CA8","latestVersionIndicator":"Yes","beginDate":"2015-04-07","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2015-04-07","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"7/19/17 jk transferred context and added registration status, CSI per Round 5 finalization task. 4/28/15 released. jc  4/7/15 VD versioned per COG WG: inc to 100 char, remove min limit, chg concept domain to assessment result. jc 1/25/13 added ACRIN Old caBIG CSI.  3/21/12 - changed origin from IVI to ACRIN.  3/5/08 - released for UoWASH FES CRF.   7/23/07-created for ACRIN PET CDEs","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"If other, specify:","url":null,"context":"COG"},{"name":"What were the other amino aci","type":"Preferred Question Text","description":"What were the other amino acid sequencing changes detected in the ALK tyrosine kinase receptor variation positive finding neoplasm?","url":null,"context":"COG"},{"name":"If tumor is positive for activating variant in ALK tyrosine kinase domain, Amino acid change(s) detected:","type":"Alternate Question Text","description":"If tumor is positive for activating variant in ALK tyrosine kinase domain, Amino acid change(s) detected:","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D70C71CC-6A4E-3009-E053-4EBD850A28A1","latestVersionIndicator":"Yes","beginDate":"2022-02-02","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2022-02-02","modifiedBy":"FEIBUSHL","dateModified":"2022-03-01","changeDescription":"2022-2-2 ak Released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}